reports
- Wedbush Research
CYBR CYBERARK SOFTWARE LTD.
BCRX BIOCRYST PHARMACEUTICALS INC.
MSFT MICROSOFT CORPORATION
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
BDTX BLACK DIAMOND THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
COGT COGENT BIOSCIENCES INC
PHVS PHARVARIS NV
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
TNGX TANGO THERAPEUTICS
ATXS INC
TYRA ASTRIA THERAPEUTICS INC
PEPG TYRA BIOSCIENCES INC
NUVL PEPGEN INC
BBOT NUVALENT INC
BRIDGEBIO ONCOLOGY THERAPEUTICS
- Laura Chico
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 36,700 shares, and restricted stock units (RSUs) covering an aggregate of 71,400 shares, of BioCryst common stock. The options and RSUs were granted as of September 2, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were gra...
- Wedbush Research
- Laura Chico
BioCryst to Present at Upcoming Investor Conference
BioCryst to Present at Upcoming Investor Conference RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on Thursday, September 4, 2025, at 9:45 a.m. ET. The link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at . About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with heredit...
BioCryst Announces Departure of Dr. Helen Thackray
BioCryst Announces Departure of Dr. Helen Thackray RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory role through the end of the year. Dr. Thackray first joined the company as a member of the board of directors in 2019 and was appointed chief research and development officer in 2021. She was a finalist internal candidate considered by the board of directors in the chief executive officer succession process....
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
MNKD MANNKIND CORP.
KURA KURA ONCOLOGY INC.
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
NTLA INTELLIA THERAPEUTICS INC.
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
ARVN ARVINAS HOLDING
RVMD REVOLUTION MEDICINES
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
TNGX TANGO THERAPEUTICS
INC
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 36,700 shares, and restricted stock units (RSUs) covering an aggregate of 89,750 shares, of BioCryst common stock. The options and RSUs were granted as of August 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in...
- Wedbush Research
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
MELI MERCADOLIBRE INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ARDX ARDELYX INC
TSEM TOWER SEMICONDUCTOR LTD
PLTR PALANTIR TECHNOLOGIES
PAY PAYMENTUS HLDGS INC
TMC THE METALS COMPANY INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
- Laura Chico
BioCryst Reports Second Quarter 2025 Financial Results and Provides Bu...
BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update —Q2 2025 ORLADEYO net revenue of $156.8 million (+45 percent y-o-y)— —Q2 2025 operating profit of $29.8 million (+239 percent y-o-y); non-GAAP operating profit of $57.0 million (+160 percent y-o-y)— —Company makes additional $50 million paydown of term debt and plans to retire all remaining term debt with proceeds of sale of European ORLADEYO business— RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2...
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NCMI NATIONAL CINEMEDIA INC.
MU MICRON TECHNOLOGY INC.
MNKD MANNKIND CORP.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
CXW CORECIVIC INC.
CTMX CYTOMX THERAPEUTICS INC.
CNK CINEMARK HOLDINGS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
NTLA INTELLIA THERAPEUTICS INC.
CVCO CAVCO INDUSTRIES INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
RCUS ARCUS BIOSCIENCES
HEAR TURTLE BEACH CORP.
SRRK SCHOLAR ROCK HOLDING CORPORATION
ARVN ARVINAS HOLDING
SMCI SUPER MICRO COMPUTER
RVMD INC.
CRSR REVOLUTION MEDICINES
PRAX CORSAIR GAMING
TVTX PRAXIS PRECISION MEDICINES
PLTK TRAVERE THERAPEUTICS INC
NUVB PLAYTIKA HOLDING
DAWN NUVATION BIO INC (A)
TNGX DAY ONE BIOPHARMACEUTICALS INC
STX TANGO THERAPEUTICS
GFS INC
SKLZ SEAGATE TECHNOLOGY HLDGS PLC
CBIO GLOBALFOUNDRIES INC
SKILLZ INC
CRESCENT BIOPHARMA INC.
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
MNKD MANNKIND CORP.
KURA KURA ONCOLOGY INC.
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
NTLA INTELLIA THERAPEUTICS INC.
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
ARVN ARVINAS HOLDING
RVMD REVOLUTION MEDICINES
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
TNGX TANGO THERAPEUTICS
INC
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Ex...
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December 31, 2025. The board has appointed Charlie Gayer, currently the company’s chief commercial officer (CCO), as the company’s next president, effective August 1, 2025, and next chief executive officer, effective Janu...
BioCryst to Report Second Quarter 2025 Financial Results on August 4
BioCryst to Report Second Quarter 2025 Financial Results on August 4 RESEARCH TRIANGLE PARK, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will report its second quarter 2025 financial results on Monday, August 4, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be ava...
- Abe Rimatzki
- Seth Basham
- Wedbush Research
PEGA PEGASYSTEMS INC.
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CVCO CAVCO INDUSTRIES INC.
APLS APELLIS PHARMACEUTICALS
TVTX TRAVERE THERAPEUTICS INC
RZLT REZOLUTE
TTD THE TRADE DESK
INC.
- Dylan Shindler
- Laura Chico
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA Nat...
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on pediatric patients under the age of 12 and their caregivers and perspectives on the importance of HAE treatments. The findings will be presented in posters at the 2025 US HAEA National Summit in Baltimore, which is taking place July 10-13, 2025. “For more than a decade, we have been...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.